These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36877285)

  • 1. Mosunetuzumab (Lunsumio) for follicular lymphoma.
    Med Lett Drugs Ther; 2023 Mar; 65(1671):e41-e42. PubMed ID: 36877285
    [No Abstract]   [Full Text] [Related]  

  • 2. Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA.
    Lin SW; Shapouri S; Parisé H; Bercaw E; Wu M; Kim E; Matasar M
    Pharmacoeconomics; 2024 May; 42(5):569-582. PubMed ID: 38300452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mosunetuzumab: First Approval.
    Kang C
    Drugs; 2022 Jul; 82(11):1229-1234. PubMed ID: 35947358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
    Budde LE; Sehn LH; Matasar M; Schuster SJ; Assouline S; Giri P; Kuruvilla J; Canales M; Dietrich S; Fay K; Ku M; Nastoupil L; Cheah CY; Wei MC; Yin S; Li CC; Huang H; Kwan A; Penuel E; Bartlett NL
    Lancet Oncol; 2022 Aug; 23(8):1055-1065. PubMed ID: 35803286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copanlisib (Aliqopa) for relapsed follicular lymphoma.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):e74-e75. PubMed ID: 29667951
    [No Abstract]   [Full Text] [Related]  

  • 6. Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting.
    Cao Y; Marcucci EC; Budde LE
    J Hematol Oncol; 2023 Jun; 16(1):69. PubMed ID: 37381053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug approval: Mosunetuzumab - third-line therapy in follicular lymphoma].
    Gondran C; Ysebaert L
    Bull Cancer; 2022 Nov; 109(11):1105-1106. PubMed ID: 36167561
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma.
    Nierengarten MB
    Cancer; 2023 May; 129(10):1465-1466. PubMed ID: 37088993
    [No Abstract]   [Full Text] [Related]  

  • 9. Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma.
    Buske C
    Lancet Oncol; 2022 Aug; 23(8):967-969. PubMed ID: 35803285
    [No Abstract]   [Full Text] [Related]  

  • 10. Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma.
    Cohen JA; Ghobadi A
    Expert Rev Anticancer Ther; 2022 Sep; 22(9):903-914. PubMed ID: 35786133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In brief: Lisocabtagene maraleucel (Breyanzi) for large B-cell lymphoma.
    Med Lett Drugs Ther; 2023 Jun; 65(1679):e104-e105. PubMed ID: 37339093
    [No Abstract]   [Full Text] [Related]  

  • 12. Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma.
    Bosch F; Kuruvilla J; Vassilakopoulos TP; Maio DD; Wei MC; Zumofen MB; Nastoupil LJ
    Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):105-121. PubMed ID: 37981564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
    Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
    Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axicabtagene ciloleucel (Yescarta) for B-cell lymphoma.
    Med Lett Drugs Ther; 2018 Jul; 60(1551):e122-e123. PubMed ID: 30036350
    [No Abstract]   [Full Text] [Related]  

  • 15. Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.
    Eltantawy A; Vallejos X; Sebea E; Evans K
    Ann Pharmacother; 2019 Sep; 53(9):954-958. PubMed ID: 30813760
    [No Abstract]   [Full Text] [Related]  

  • 16. Copanlisib for the treatment of adults with relapsed follicular lymphoma.
    Magagnoli M; Carlo-Stella C; Santoro A
    Expert Rev Clin Pharmacol; 2020 Aug; 13(8):813-823. PubMed ID: 32576028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New European approvals: Tisagenlecleucel and Axicabtagene ciloleucel CAR-T cells - Follicular lymphoma after at least two and three prior lines of therapy].
    Cordeil S; Bachy E
    Bull Cancer; 2022 Nov; 109(11):1106-1108. PubMed ID: 36088178
    [No Abstract]   [Full Text] [Related]  

  • 18. How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?
    Huguet M; Raimond V; Kaltenbach E; Augusto V; Perrier L
    Bull Cancer; 2021 Dec; 108(12):1170-1180. PubMed ID: 34561025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
    Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
    Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.
    Dhillon S
    Target Oncol; 2017 Apr; 12(2):255-262. PubMed ID: 28324270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.